Trial · NCT03197870
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps | Razuprotafib 15mg Twice Daily | 0 | eyes | ||
| Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps | Razuprotafib 15mg Daily | 5 | eyes | ||
| Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps | Placebo Twice Daily | 2 | eyes | ||
| Summary of Subjects With a Worsening in the Study Eye DRSS of ≥ 2 Steps at Week 48 | AKB-9778 15mg Daily | 5 | study eyes | ||
| Summary of Subjects With a Worsening in the Study Eye DRSS of ≥ 2 Steps at Week 48 | AKB-9778 15mg Twice Daily | 6 | study eyes | ||
| Summary of Subjects With a Worsening in the Study Eye DRSS of ≥ 2 Steps at Week 48 | Placebo Twice Daily | 4 | study eyes | ||
| Mean Change From Baseline in DRSS in the Study Eye at Week 48 | AKB-9778 15mg Daily | 5.0 | Standard Deviation 1.15 | score on a scale | |
| Mean Change From Baseline in DRSS in the Study Eye at Week 48 | AKB-9778 15mg Twice Daily | 4.9 | Standard Deviation 1.55 | score on a scale | |
| Mean Change From Baseline in DRSS in the Study Eye at Week 48 | Placebo Twice Daily | 4.8 | Standard Deviation 1.35 | score on a scale | |
| Summary of Subjects With an Improvement or Worsening in the Study Eye DRSS of ≥ 3 Steps at Week 48. | AKB-9778 15mg Daily | Worsening ≥3 steps | 3 | study eyes | |
| Summary of Subjects With an Improvement or Worsening in the Study Eye DRSS of ≥ 3 Steps at Week 48. | AKB-9778 15mg Twice Daily | Worsening ≥3 steps | 4 | study eyes | |
| Summary of Subjects With an Improvement or Worsening in the Study Eye DRSS of ≥ 3 Steps at Week 48. | Placebo Twice Daily | Worsening ≥3 steps | 3 | study eyes | |
| Summary of Subjects With an Improvement or Worsening in the Study Eye DRSS of ≥ 3 Steps at Week 48. | AKB-9778 15mg Daily | Improvement ≥3 steps | 0 | study eyes | |
| Summary of Subjects With an Improvement or Worsening in the Study Eye DRSS of ≥ 3 Steps at Week 48. | AKB-9778 15mg Twice Daily | Improvement ≥3 steps | 0 | study eyes | |
| Summary of Subjects With an Improvement or Worsening in the Study Eye DRSS of ≥ 3 Steps at Week 48. | Placebo Twice Daily | Improvement ≥3 steps | 0 | study eyes | |
Subjects With Criterion Step Improvement in DRSS at Week 48/EOT (>=2 Steps Improvement in the Study Eye for Patients With Non-qualified Fellow Eye and >=3 Steps Improvement on the Person Scale for Patients With Qualified Fellow Eyes) | AKB-9778 15mg Daily | 0 | Participants | ||
Subjects With Criterion Step Improvement in DRSS at Week 48/EOT (>=2 Steps Improvement in the Study Eye for Patients With Non-qualified Fellow Eye and >=3 Steps Improvement on the Person Scale for Patients With Qualified Fellow Eyes) | AKB-9778 15mg Twice Daily | 5 | Participants | ||
Subjects With Criterion Step Improvement in DRSS at Week 48/EOT (>=2 Steps Improvement in the Study Eye for Patients With Non-qualified Fellow Eye and >=3 Steps Improvement on the Person Scale for Patients With Qualified Fellow Eyes) | Placebo Twice Daily | 1 | Participants | ||
Subjects With Criterion Step Improvement in DRSS at Week 48/EOT (>=2 Steps Improvement in the Study Eye for Patients With Non-qualified Fellow Eye and >=3 Steps Improvement on the Binocular Scale for Patients With Qualified Fellow Eyes) | AKB-9778 15mg Daily | 0 | Participants | ||
Subjects With Criterion Step Improvement in DRSS at Week 48/EOT (>=2 Steps Improvement in the Study Eye for Patients With Non-qualified Fellow Eye and >=3 Steps Improvement on the Binocular Scale for Patients With Qualified Fellow Eyes) | AKB-9778 15mg Twice Daily | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03197870/results